Research paperβ-Lactam analogues of COMBRETASTATIN A-4 (cas 117048-59-6) prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells

Add time:08/25/2019    Source:sciencedirect.com

Glucuronidation by uridine 5-diphosphoglucuronosyl transferase enzymes (UGTs) is a cause of intrinsic drug resistance in cancer cells. Glucuronidation of COMBRETASTATIN A-4 (cas 117048-59-6) (CA-4) was previously identified as a mechanism of resistance in hepatocellular cancer cells. Herein, we propose chemical manipulation of β-lactam bridged analogues of Combretastatin A-4 as a novel means of overcoming drug resistance associated with glucuronidation due to the expression of UGTs in the CA-4 resistant human colon cancer HT-29 cells. The alkene bridge of CA-4 is replaced with a β-lactam ring to circumvent potential isomerisation while the potential sites of glucuronate conjugation are deleted in the novel 3-substituted-1,4-diaryl-2-azetidinone analogues of CA-4. We hypothesise that glucuronidation of CA-4 is the mechanism of drug resistance in HT-29 cells. Ring B thioether containing 2-azetidinone analogues of CA-4 such as 4-(4-(methylthio)phenyl)-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (27) and 3-hydroxy-4-(4-(methylthio)phenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (45) were identified as the most potent inhibitors of tumour cell growth, independent of UGT status, displaying antiproliferative activity in the low nanomolar range. These compounds also disrupted the microtubular structure in MCF-7 and HT-29 cells, and caused G2/M arrest and apoptosis. Taken together, these findings highlight the potential of chemical manipulation as a means of overcoming glucuronidation attributed drug resistance in CA-4 resistant human colon cancer HT-29 cells, allowing the development of therapeutically superior analogues.

We also recommend Trading Suppliers and Manufacturers of COMBRETASTATIN A-4 (cas 117048-59-6). Pls Click Website Link as below: cas 117048-59-6 suppliers

Prev:Design and synthesis of cis-restricted benzimidazole and benzothiazole mimics of COMBRETASTATIN A-4 (cas 117048-59-6) as antimitotic agents with apoptosis inducing ability
Next:Original articleDesign and synthesis of pironetin analogue/COMBRETASTATIN A-4 (cas 117048-59-6) hybrids containing a 1,2,3-triazole ring and evaluation of their cytotoxic activity)